Company Filing History:
Years Active: 2007-2013
Title: Vendela Parrow: Innovator in Protein Kinase Inhibition
Introduction
Vendela Parrow is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of biochemistry, particularly in the development of compounds that act as inhibitors of protein kinases. With a total of 2 patents, her work has implications for the treatment of various hematological malignancies and other medical disorders.
Latest Patents
One of her latest patents is focused on amino substituted pyrazines as inhibitors of protein kinases. This invention relates to compounds of the general formula (I), which can inhibit the Fms-like tyrosine kinase 3 (FLT3). The compounds are not only useful in therapy but also in pharmaceutical compositions for the preparation of medicaments aimed at treating conditions such as acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), and skin disorders like psoriasis. Another patent involves methods for identifying active compounds that modulate the effects of cytokine class I receptor binding compounds. This invention is particularly relevant for decreasing IGF-1 levels in cells and treating disorders caused by hormone dysregulation.
Career Highlights
Throughout her career, Vendela has worked with prominent companies in the pharmaceutical sector, including Biovitrum AB and Akinion Pharmaceuticals AB. Her experience in these organizations has allowed her to contribute to significant advancements in medical research and drug development.
Collaborations
Vendela has collaborated with esteemed colleagues such as Lotta Moréus and Annika Jenmalm Jensen. These partnerships have further enriched her research and innovation efforts.
Conclusion
Vendela Parrow is a pioneering inventor whose work in protein kinase inhibition and hormone dysregulation has the potential to transform therapeutic approaches in medicine. Her contributions continue to impact the field significantly.